Informazioni cliniche
La famiglia degli herpesvirus comprende più di 100 tipi di virus diversi, otto dei quali possono causare infezioni nell'uomo. Questi cosiddetti herpesvirus umani comprendono il virus Herpes simplex di tipo 1 e 2 (HSV-1 e -2), il virus varicella-zoster (VZV), il virus Epstein-Barr (EBV), il Citomegalovirus (CMV), gli herpesvirus umani 6 e 7 (HHV-6 e -7) e l'herpesvirus umano 8 (HHV-8), associato al sarcoma di Kaposi. Nonostante le grandi somiglianze strutturali tra i diversi patogeni, l'infezione da herpesvirus può causare malattie molto diverse tra loro, ad esempio l'herpes labiale o genitale, la varicella, il fuoco di Sant‘Antonio, la malattia del bacio o diversi tipi di cancro. Durante la gravidanza, soprattutto l'infezione primaria con particolari herpesvirus può portare a gravi lesioni o addirittura alla perdita del bambino. Attualmente esiste solo un vaccino contro il VZV. Dopo l'infezione primaria, che spesso procede in modo asintomatico, gli herpesvirus persistono per tutta la vita nell'organismo in uno stato latente e possono riattivarsi in un momento successivo, ad esempio a causa di un sistema immunitario indebolito, e causare (di nuovo) sintomi.
Diagnostica
La diagnostica di laboratorio degli herpesvirus si basa su metodi di rilevamento diretti o indiretti. I metodi diretti, che sono particolarmente importanti per la diagnosi di infezioni acute o in persone immunodepresse, includono, ad esempio, la coltura del virus o i test basati sulla PCR, in cui vengono rilevati gli acidi nucleici virali. Come materiale di campionamento si utilizzano: liquido vescicolare, strisci di pelle o di mucosa, sangue, liquor o liquido di lavaggio broncoalveolare. Se l'anticorpo specifico per l'herpesvirus viene rilevato nel siero, nel plasma o nel liquor del paziente, questo viene considerato un rilevamento indiretto del patogeno. La rilevazione degli anticorpi non solo consente di trarre conclusioni su quale virus sia presente nel paziente, ma può anche contribuire alla differenziazione di infezioni primarie e ricorrenti. EUROIMMUN offre un'ampia gamma di prodotti per la rilevazione delle infezioni da herpesvirus, che comprendono sia la rilevazione degli anticorpi che i metodi di rilevazione diretta.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ELISA |
CSQ pair of controls anti-Cytomegalovirus (IgG) |
IgG |
02 x 20 |
CK 2570-0220-L G | |||
| ELISA |
CSQ pair of controls anti-EBV-CA (IgG) |
IgG |
02 x 20 |
CK 2791-0220-L G | |||
| ELISA |
CSF: Anti-CMV ELISA (IgG) cytomegalovirus Sample type: CSF/serum pair |
antigen-coated microplate wells |
native antigens from CMV |
5/25/50/100 U | IgG |
96 x 01 |
EI 2570-9601-L G |
| ELISA |
CSF: Anti-EBV-CA-ELISA (IgG) Epstein-Barr virus capsid antigen Sample type: CSF/serum pair |
antigen-coated microplate wells |
native, mixture of several viral capsid antigens |
5/25/50/100 U | IgG |
96 x 01 |
EI 2791-9601-L G |
| ELISA |
CSQ pair of controls anti-HSV-1/2 Pool (IgG) |
IgG |
02 x 20 |
CK 2531-0220-1 L G | |||
| ELISA |
CSF: Anti-HSV-1/2 Pool ELISA (IgG) herpes simplex virus Sample type: CSF/serum pair |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
5/25/50/100/175/230 U/ml | IgG |
96 x 01 |
EI 2531-9601-1 L G |
| ELISA |
CSQ pair of controls anti-VZV (IgG) |
IgG |
02 x 20 |
CK 2650-0220-L G | |||
| IIFT | HHV-6 | infected cells | EU 30 | IgG IgM IgG IgM IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 20 x 05 20 x 05 20 x 10 20 x 10 |
FI 2536-1005 G FI 2536-1005 M FI 2536-1010 G FI 2536-1010 M FI 2536-2005 G FI 2536-2005 M FI 2536-2010 G FI 2536-2010 M |
|
| IIFT |
Epstein-Barr virus capsid antigen (EBV-CA) |
expressing cells | P3HR1 | IgG EB IgM EB IgG EB IgM EB IgM EB IgG EB |
10 x 05 10 x 05 10 x 10 10 x 10 20 x 05 20 x 10 |
FI 2791-1005 G FI 2791-1005 M FI 2791-1010 G FI 2791-1010 M FI 2791-2005 M FI 2791-2010 G |
|
| IIFT |
Epstein-Barr virus nuclear antigen (EBNA, complement-fixing antibodies) |
expressing cells | Raji | C3c EB |
10 x 10 |
FI 2793-1010 C | |
| IIFT |
Epstein-Barr virus early antigen (EBV-EA) |
expressing cells | EU 33 | IgG EB IgG EB |
10 x 05 10 x 10 |
FI 2795-1005 G FI 2795-1010 G |
|
| IIFT |
BIOCHIP Sequence EBV fields A and B: EBV-CA (IgG) field C: EBV-CA (IgM) field D: EBV-EA field E: EBNA |
expressing cells expressing cells expressing cells expressing cells |
P3HR1 P3HR1 EU 33 Raji |
Aviditätsbestimmung Aviditätsbestimmung Aviditätsbestimmung Aviditätsbestimmung |
10 x 01 10 x 02 20 x 01 20 x 02 |
FI 2799-1001-1 X FI 2799-1002-1 X FI 2799-2001-1 X FI 2799-2002-1 X |
|
| IIFT |
EUROPLUS BIOCHIP Sequence EBV field A: EBV-CA (IgG), gp125 ag, p19 ag field B: EBV-CA (IgG) field C: EBV-CA (IgM), gp125 ag, p19 ag field D: EBV-EA field E: EBNA |
expr. cells, gp125/p19/ ag-free BIOCHIP expressing cells expressing cells expr. cells, gp125/p19/ ag-free BIOCHIP expressing cells |
P3HR1, native/rec. EU 120 P3HR1 P3HR1, native/rec. EU 120 EU 33 Raji |
Aviditätsbestimmung Aviditätsbestimmung Aviditätsbestimmung Aviditätsbestimmung |
10 x 01 10 x 02 20 x 01 20 x 02 |
FI 2799-1001-21 X FI 2799-1002-21 X FI 2799-2001-21 X FI 2799-2002-21 X |
|
| IIFT | HHV-6 EUROPattern | infected cells | EU 30 | IgG EB IgM EB IgG EB IgM EB IgG EB IgM EB IgG EB IgM EB |
10 x 05 10 x 05 10 x 10 10 x 10 20 x 05 20 x 05 20 x 10 20 x 10 |
FR 2536-1005 G FR 2536-1005 M FR 2536-1010 G FR 2536-1010 M FR 2536-2005 G FR 2536-2005 M FR 2536-2010 G FR 2536-2010 M |
|
| ELISA |
Anti-EBV-CA ELISA (IgA) Epstein-Barr virus capsid antigen |
antigen-coated microplate wells |
native, mixture of several viral capsid antigens |
semi-quantitative | IgA |
96 x 01 |
EI 2791-9601 A |
| ELISA |
Anti-EBV-CA ELISA (IgG) Epstein-Barr virus capsid antigen |
antigen-coated microplate wells |
native, mixture of several viral capsid antigens |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2791-9601 G |
| ELISA |
Anti-EBV-CA ELISA (IgM) Epstein-Barr virus capsid antigen |
antigen-coated microplate wells |
native gp125 of EBV |
semi-quantitative | IgM |
96 x 01 |
EI 2791-9601 M |
| ELISA |
Avidity: Anti-EBV-CA-ELISA (IgG) Epstein-Barr virus capsid antigen avidity determination |
antigen-coated microplate wells |
native, mixture of several viral capsid antigens |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2791-9601-1 G |
| ELISA |
Anti-EBNA-1 ELISA (IgG) Epstein-Barr virus nuclear antigen |
antigen-coated microplate wells |
recombinant EBNA-1 from EBV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2793-9601 G |
| ELISA |
Anti-EBV-EA-D ELISA (IgA) Epstein-Barr virus early antigen |
antigen-coated microplate wells |
recombinant early antigen D from EBV |
semi-quantitative | IgA |
96 x 01 |
EI 2795-9601 A |
| ELISA |
Anti-EBV-EA-D ELISA (IgG) Epstein-Barr virus early antigen |
antigen-coated microplate wells |
recombinant early antigen D from EBV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2795-9601 G |
| ELISA |
Anti-EBV-EA-D ELISA (IgM) Epstein-Barr virus early antigen |
antigen-coated microplate wells |
recombinant early antigen D from EBV |
semi-quantitative | IgM |
96 x 01 |
EI 2795-9601 M |
| EUROLINE |
positive control serum: IgG, human, 50x concentrated for EBV-Profil 2 G |
IgG |
05 x 07 |
CL 2790-0507-12 G | |||
| EUROLINE |
positive control serum: IgM, human, 50x concentrated for EBV-Profil 2 M |
IgM |
05 x 07 |
CL 2790-0507-12 M | |||
| EUROLINE |
EUROLINE Anti-EBV Profile 2 (IgM) (VCA gp125, VCA p19, EBNA-1, p22, EA-D separately) |
EUROLINE | IgM IgM IgM |
05 x 10 16 x 01 64 x 01 |
DN 2790-0510-2 M DN 2790-1601-2 M DN 2790-6401-2 M |
||
| EUROLINE |
EUROLINE Anti-EBV (IgM) (VCA gp125, VCA p19, EA-D separately) |
EUROLINE | IgM IgM IgM |
05 x 10 16 x 01 64 x 01 |
DN 2790-0510-4 M DN 2790-1601-4 M DN 2790-6401-4 M |
||
| EUROLINE |
EUROLINE Anti-EBV Profile 2 (IgG) (VCA gp125, VCA p19, EBNA-1, p22, EA-D separately) |
EUROLINE | IgG IgG IgG |
16 x 01 50 x 01 64 x 01 |
DN 2790-1601-2 G DN 2790-5001-2 G DN 2790-6401-2 G |
||
| EUROLINE |
EUROLINE Anti-EBV (IgG) (VCA gp125, VCA p19, EBNA-1, p22. EA-D separately) |
EUROLINE | IgG IgG IgG |
16 x 01 50 x 01 64 x 01 |
DN 2790-1601-4 G DN 2790-5001-4 G DN 2790-6401-4 G |
||
| ChLIA | IDS EBV VCA IgG | antigenic coated magnetic particles | Capsid antigen |
quantitative |
100 x 01 |
IS-ID58011 | |
| ChLIA | IDS EBV VCA IgM | antigenic coated magnetic particles | Capsid antigen |
quantitative |
100 x 01 |
IS-ID58021 | |
| ChLIA | IDS EBV EBNA-1 IgG | antigenic coated magnetic particles | EBNA-1 |
quantitative |
100 x 01 |
IS-ID58031 | |
| ChLIA | IDS EBV EA IgG | antigenic coated magnetic particles | EA-D antigen |
quantitative |
50 x 01 |
IS-ID58041 | |
| ChLIA | IDS EBV Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID58301 | ||
| ChLIA |
Anti-EBV-CA ChLIA (IgG) Epstein-Barr virus capsid antigen |
Antigen-coated magnetic particles |
recombinant p18, p23, gp125 |
quantitative | IgG |
100 x 1 |
LI 2791-10010 G |
| ChLIA |
Anti-EBV-CA ChLIA (IgM) Epstein-Barr virus capsid antigen |
Antigen-coated magnetic particles |
recombinant p18, gp125 |
quantitative | IgM |
100 x 1 |
LI 2791-10010 M |
| ChLIA |
Anti-EBNA-1 ChLIA (IgG) Epstein-Barr virus nuclear antigen |
Antigen-coated magnetic particles |
recombinant EBNA-1 |
quantitative | IgG |
100 x 1 |
LI 2793-10010 G |
| ChLIA |
Control set Anti-EBV-CA ChLIA (IgG) Epstein-Barr virus capsid antigen |
2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2791-20210 G | ||
| ChLIA |
Control set Anti-EBV-CA ChLIA (IgM) Epstein-Barr virus capsid antigen |
2 x 0.5 ml control 1/2 | IgM |
02 x 02 |
LR 2791-20210 M | ||
| ChLIA |
Control set Anti-EBNA-1 ChLIA (IgG) Epstein-Barr virus nuclear antigen |
2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2793-20210 G | ||
| MICROBLOT | EUROMicroblot Anti-EBV (IgG) | IgG |
96 x 01 |
KN 2790-9601 G | |||
| MICROBLOT | EUROMicroblot Anti-EBV (IgM) | IgM |
96 x 01 |
KN 2790-9601 M | |||
| ELISA |
Anti-CMV ELISA (IgG) cytomegalovirus |
antigen-coated microplate wells |
native antigens from CMV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2570-9601 G |
| ELISA |
Anti-CMV ELISA (IgM) cytomegalovirus |
antigen-coated microplate wells |
native antigens from CMV |
semi-quantitative | IgM |
96 x 01 |
EI 2570-9601 M |
| ELISA |
Avidity: Anti-CMV ELISA (IgG) cytomegalovirus avidity determination |
antigen-coated microplate wells |
native antigens from CMV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2570-9601-1 G |
| ELISA |
Anti-CMV p52 ELISA (IgM) cytomegalovirus p52 antigen from CMV |
antigen-coated microplate wells |
native antigens from CMV |
semi-quantitative | IgM |
96 x 01 |
EI 2570-9601-2 M |
| ELISA |
Anti-CMV gB ELISA (IgG) cytomegalovirus glycoprotein B glycoprotein B antigen from CMV |
antigen-coated microplate wells |
recombinant glycoprotein B antigen from CMV |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2570-9601-3 G |
| EUROLINE |
positive control serum: IgG, human, 50x concentrated for CMV |
IgG |
05 x 07 |
CL 2570-0507 G | |||
| EUROLINE |
positive control serum: IgM, human, 50x concentrated for CMV |
IgM |
05 x 07 |
CL 2570-0507 M | |||
| EUROLINE | EUROLINE Anti-CMV (IgG) | EUROLINE | IgG IgG IgG |
16 x 01 50 x 01 64 x 01 |
DN 2570-1601-2 G DN 2570-5001-2 G DN 2570-6401-2 G |
||
| EUROLINE | EUROLINE Anti-CMV (IgM) | EUROLINE | IgM IgM IgM |
16 x 01 50 x 01 64 x 01 |
DN 2570-1601-2 M DN 2570-5001-2 M DN 2570-6401-2 M |
||
| ChLIA | IDS CMV IgG | antigenic coated magnetic particles | CMV antigen |
qualitative |
100 x 01 |
IS-ID54011 | |
| ChLIA | IDS CMV IgM | antigenic coated magnetic particles | CMV antigen |
qualitative |
100 x 01 |
IS-ID54021 | |
| ChLIA | IDS CMV Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID54301 | ||
| ChLIA | IDS CMV IgG Avidity | antigenic coated magnetic particles | CMV antigen |
qualitative |
50 x 01 |
IS-ID55011 | |
| ChLIA | IDS CMV Avidity Control Set | 3 x 1.0 ml Control 1/2 | human serum |
2 concentrations |
IS-ID55301 | ||
| ELISA |
Anti-HSV-1/2 Pool ELISA (IgG) herpes simplex virus native antigens from HSV-1 and HSV-2 |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2531-9601-1 G |
| ELISA |
Anti-HSV-1/2 Pool ELISA (IgM) herpes simplex virus native antigens from HSV-1 and HSV-2 |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
semi-quantitative | IgM |
96 x 01 |
EI 2531-9601-1 M |
| ELISA |
Anti-HSV-1 (gC1) ELISA (IgG) herpes simplex virus 1 recombinant glycoprotein C1 from HSV-1 |
antigen-coated microplate wells |
recombinant glycoprotein C1 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2531-9601-2 G |
| ELISA |
Anti-HSV-2 (gG2) ELISA (IgG) herpes simplex virus 2 recombinant glycoprotein G2 from HSV-2 |
antigen-coated microplate wells |
recombinant glycoprotein G2 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2532-9601-2 G |
| WESTERNBLOT |
antibodies against Herpes simplex virus (HSV) IgG positive control |
IgG |
50 x 05 |
CW 2531-5005 G | |||
| WESTERNBLOT |
Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgG) Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2 |
Westernblot |
whole antigen, SDS extract of HSV-1 plus purified gG2 |
IgG |
16 x 01 |
DY 2531-1601-1 G | |
| WESTERNBLOT |
Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgM) Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2 |
Westernblot |
whole antigen, SDS extract of HSV-1 plus purified gG2 |
IgM |
16 x 01 |
DY 2531-1601-1 M | |
| ChLIA | IDS HSV-1 IgG | antigenic coated magnetic particles | gG1 antigen |
quantitative |
100 x 01 |
IS-ID56011 | |
| ChLIA | IDS HSV-2 IgG | antigenic coated magnetic particles | gG2 antigen |
quantitative |
100 x 01 |
IS-ID56021 | |
| ChLIA | IDS HSV 1/2 IgG Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID56301 | ||
| ChLIA | IDS HSV 1/2 IgM | antigenic coated magnetic particles | gG1 and gG2 antigens |
quantitative |
100 x 01 |
IS-ID57011 | |
| ChLIA | IDS HSV 1/2 IgM Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID57301 | ||
| ChLIA | Anti-Herpes simplex virus 1 ChLIA (IgG) | Antigen-coated magnetic particles | recombinant gG1 | quantitative | IgG |
100 x 1 |
LI 2531-10010 G |
| ChLIA | Anti-Herpes simplex virus 2 ChLIA (IgG) | Antigen-coated magnetic particles | rekombinant gG2 | quantitative | IgG |
100 x 1 |
LI 2532-10010 G |
| ChLIA | Control set Anti-HSV 1 ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2531-20210 G | ||
| ChLIA | Control set Anti-HSV 2 ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2532-20210 G | ||
| IIFT |
Varicella zoster virus (VZV) |
infected cells | EU 168 | IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2650-1005 G FI 2650-1005 M FI 2650-1010 G FI 2650-1010 M |
|
| ELISA |
Anti-VZV ELISA (IgA) Varicella zoster virus |
antigen-coated microplate wells |
native antigens from VZV |
semi-quantitative | IgA |
96 x 01 |
EI 2650-9601 A |
| ELISA |
Anti-VZV ELISA (IgG) Varicella zoster virus |
antigen-coated microplate wells |
native antigens from VZV |
10/100/500/5000 IU/l | IgG |
96 x 01 |
EI 2650-9601 G |
| ELISA |
Anti-VZV ELISA (IgM) Varicella zoster virus |
antigen-coated microplate wells |
native antigens from VZV |
semi-quantitative | IgM |
96 x 01 |
EI 2650-9601 M |
| ELISA |
Avidity: Anti-VZV ELISA (IgG) Varicella zoster virus avidity determination |
antigen-coated microplate wells |
native antigens from VZV |
10/100/500/5000 IU/l | IgG |
96 x 01 |
EI 2650-9601-1 G |
| ELISA |
Anti-VZV ELISA 2.0 (IgG) Varicella zoster virus |
antigen-coated microplate wells |
native antigens from VZV | IgG |
96 x 01 |
EI 2650-9601-2 G | |
| ELISA |
Anti-VZV Glycoprotein ELISA (IgM) Varicella zoster virus |
antigen-coated microplate wells |
native glycoproteins from VZV |
semi-quantitative | IgM |
96 x 01 |
EI 2650-9601-2 M |
| ChLIA | IDS VZV IgG | antigenic coated magnetic particles | VZV virus antigen |
quantitative |
50 x 01 |
IS-ID59031 | |
| ChLIA | IDS MMV IgG Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID59301 | ||
| ChLIA | IDS VZV IgM | antigenic coated magnetic particles | VZV virus antigen |
quantitative |
50 x 01 |
IS-ID60031 | |
| ChLIA | IDS MMV IgM Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID60301 | ||
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||